

Tardive Dyskinesia Therapeutics Market Forecasts to 2034 – Global Analysis By Product Type (Valbenazine, Deutetrabenazine, Clonazepam, Vitamin E, Benzodiazepines, Ondansetron, Tetrabenazine, Reserpine, Propranolol and Dopamine-Depleting Agents), Disease Type, Route Of Administration, Distribution Channel and By Geography

<https://marketpublishers.com/r/T2FB72B881BEEN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: T2FB72B881BEEN

Abstracts

According to Statistics MRC, the Global Tardive Dyskinesia Therapeutics Market is accounted for \$3.4 billion in 2026 and is expected to reach \$8.0billion by 2034 growing at a CAGR of 11.1% during the forecast period. A drug-induced movement condition called tardive dyskinesia (TD) results in uncontrollably moving the tongue, face, torso, and limbs. It is a side effect brought on by extended use of specific psychiatric drug classes, such antipsychotics. Although they sometimes afflict other patients as well, the illness is most frequent among those who have been taken long-term antipsychotic drugs for schizophrenia, schizoaffective disorder, or bipolar disorder.

According to an article published by John Wiley & Sons, Inc., in August 2022, the prevalence of tardive dyskinesia in Europe is 23.3% amongst psychiatric patients receiving treatment with antipsychotics.

Market Dynamics:

Driver:

Rising prevalence of tardive dyskinesia

Increased consciousness encourages early identification and action, which may lessen the severity of symptoms. Research progresses lead to the creation of more specialized drugs and therapies, providing impacted people with more individualized care. Furthermore, greater awareness encourages financing for additional research, which spurs creativity and reveals fresh approaches to tardive dyskinesia therapy and prevention, eventually enhancing the quality of life for individuals affected by the disorder.

Restraint:

Complexity in management

The management of tardive dyskinesia frequently entails a mix of strategies, such as changing current prescriptions or adding new ones. This intricacy can make treatment difficult, particularly when juggling the requirement to manage the underlying condition for which the original medication was prescribed. Therapeutic options for management have a range of side effects, from mild to severe, which may require close monitoring and management.

Opportunity:

Increased awareness and diagnosis

Early detection enables timely management, which may slow its course and enhance patient outcomes. Increased knowledge encourages healthcare professionals to monitor patients proactively, which makes it easier to control symptoms by promptly changing prescription schedules or using other therapies. Moreover, better knowledge promotes patient education and support, lessens stigma, and encourages a more compassionate approach to healthcare. This all-encompassing strategy eventually improves people's quality of life, which fuels market expansion.

Threat:

Limited R&D investment by pharmaceutical companies

One of the major challenges of rare disease drugs in terms of research and development is the small patient population available for clinical trials. Only a few hundred or few thousand patients with rare diseases are accessible for clinical trials. Rare diseases afflict a tiny population. Furthermore, because research may be

expensive and have hazy returns on investment, pharmaceutical corporations could be reluctant to fund it.

Covid-19 Impact:

The pandemic caused disruptions in healthcare services globally, affecting regular check-ups, access to specialists, and availability of in-person treatments. This led to delays or interruptions in treatment for many individuals with tardive dyskinesia. COVID-19 impacted the progress of ongoing clinical trials and research studies related to tardive dyskinesia. Some trials might have been delayed or modified due to restrictions on in-person visits and enrollment challenges.

The deutetrabenazine segment is expected to be the largest during the forecast period

The deutetrabenazine segment is expected to be the largest during the forecast period. Its deuterium substitution enhances its efficacy and safety profile by prolonging its half-life, leading to fewer dose-related side effects and improved patient adherence. This compound demonstrates potential in reducing involuntary movements associated with Tardive Dyskinesia while offering a more consistent and manageable treatment approach.

The tardive dystonia segment is expected to have the highest CAGR during the forecast period

The tardive dystonia segment is expected to have the highest CAGR during the forecast period. Tardive dystonia, a subtype of tardive dyskinesia, specifically involves sustained muscle contractions causing repetitive, twisting movements or abnormal postures. Sometimes, adjusting or discontinuing the medications that trigger tardive dystonia can lead to improvement or resolution of symptoms. However, this must be carefully managed by a healthcare professional to balance the benefits of the medication with the risk of worsening psychiatric conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Several pharmaceutical companies have been investing in developing medications specifically targeted to manage symptoms. These treatments aim to alleviate the involuntary movements associated with the condition, thereby improving the quality of life for affected individuals. The market has shown growth in terms of advancements in

therapeutic options and the growing acceptance of these treatments among healthcare providers.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to rising healthcare awareness, improving diagnostic techniques, and an aging population. Pharmaceutical companies were working on developing new treatments and medications targeting symptoms, aiming to address the unmet medical needs in this area. Collaborations between local and global pharmaceutical companies, as well as advancements in technology for diagnosis and treatment, were also contributing to the expansion of the market in the region.

Key players in the market

Some of the key players in Tardive Dyskinesia Therapeutics market include Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, AbbVie Inc , Sanis, SteriMax Inc., Adamas Pharmaceuticals, Inc , Reddys Laboratories Ltd, Mylan N.V., Bausch Health, Johnson & Johnson Services, Lupin Pharmaceuticals Inc, Novartis AG, Baxter, Amgen Inc, Pfizer Inc and Medicure Inc.

Key Developments:

In February 2023, Teva Pharmaceuticals announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. have entered into a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, which is intended for use as tardive dyskinesia therapeutics in Japan.

Product Types Covered:

Valbenazine

Deutetrabenazine

Clonazepam

Vitamin E

Benzodiazepines

Ondansetron

Tetrabenazine

Reserpine

Propranolol

Dopamine-Depleting Agents

Disease Types Covered:

Tardive akathisia

Tardive Orofacial Dyskinesia

Tardive Dystonia

Tardive Blepharospasm

Tardive Tics

Route Of Administration Covered:

Oral

Injectable

Distribution Channels Covered:

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

Other Distribution Channels

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY PRODUCT TYPE

- 5.1 Introduction
- 5.2 Valbenazine
- 5.3 Deutetrabenazine
- 5.4 Clonazepam
- 5.5 Vitamin E
- 5.6 Benzodiazepines
- 5.7 Ondansetron
- 5.8 Tetrabenazine
- 5.9 Reserpine
- 5.10 Propranolol
- 5.11 Dopamine-Depleting Agents

6 GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISEASE TYPE

- 6.1 Introduction
- 6.2 Tardive akathisia
- 6.3 Tardive Orofacial Dyskinesia
- 6.4 Tardive Dystonia
- 6.5 Tardive Blepharospasm
- 6.6 Tardive Tics

7 GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

- 7.1 Introduction
- 7.2 Oral
- 7.3 Injectable

8 GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

- 8.1 Introduction
- 8.2 Hospital Pharmacies
- 8.3 Drug Stores & Retail Pharmacies
- 8.4 Online Pharmacies
- 8.5 Other Distribution Channels

9 GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US
 - 9.2.2 Canada
 - 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific
- 9.5 South America
 - 9.5.1 Argentina
 - 9.5.2 Brazil
 - 9.5.3 Chile
 - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
 - 9.6.1 Saudi Arabia
 - 9.6.2 UAE
 - 9.6.3 Qatar
 - 9.6.4 South Africa
 - 9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions

10.5 Other Key Strategies

11 COMPANY PROFILING

11.1 Mitsubishi Tanabe Pharma Corporation

11.2 Luye Pharma Group

11.3 Teva Pharmaceutical Industries Ltd.

11.4 Neurocrine Biosciences, Inc.

11.5 SOM BIOTECH

11.6 Sun Pharmaceutical Industries Ltd

11.7 AbbVie Inc

11.8 Sanis

11.9 SteriMax Inc.

11.10 Adamas Pharmaceuticals, Inc

11.11 Reddys Laboratories Ltd

11.12 Mylan N.V.

11.13 Bausch Health

11.14 Johnson & Johnson Services

11.15 Lupin Pharmaceuticals Inc

11.16 Novartis AG

11.17 Baxter

11.18 Amgen Inc

11.19 Pfizer Inc

11.20 Medicure Inc

List Of Tables

LIST OF TABLES

- Table 1 Global Tardive Dyskinesia Therapeutics Market Outlook, By Region (2023–2034) (\$MN)
- Table 2 Global Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)
- Table 3 Global Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)
- Table 4 Global Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)
- Table 5 Global Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2023–2034) (\$MN)
- Table 6 Global Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2023–2034) (\$MN)
- Table 7 Global Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2023–2034) (\$MN)
- Table 8 Global Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2023–2034) (\$MN)
- Table 9 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2023–2034) (\$MN)
- Table 10 Global Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2023–2034) (\$MN)
- Table 11 Global Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2023–2034) (\$MN)
- Table 12 Global Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)
- Table 13 Global Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2023–2034) (\$MN)
- Table 14 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2023–2034) (\$MN)
- Table 15 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)
- Table 16 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2023–2034) (\$MN)
- Table 17 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)
- Table 18 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics

(2023–2034) (\$MN)

Table 19 Global Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 20 Global Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 21 Global Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 22 Global Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 23 Global Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 24 Global Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 25 Global Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 26 Global Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 27 North America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2023–2034) (\$MN)

Table 28 North America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)

Table 29 North America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)

Table 30 North America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)

Table 31 North America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2023–2034) (\$MN)

Table 32 North America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2023–2034) (\$MN)

Table 33 North America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2023–2034) (\$MN)

Table 34 North America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2023–2034) (\$MN)

Table 35 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2023–2034) (\$MN)

Table 36 North America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2023–2034) (\$MN)

Table 37 North America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2023–2034) (\$MN)

Table 38 North America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)

Table 39 North America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2023–2034) (\$MN)

Table 40 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2023–2034) (\$MN)

Table 41 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)

Table 42 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2023–2034) (\$MN)

Table 43 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)

Table 44 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2023–2034) (\$MN)

Table 45 North America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 46 North America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 47 North America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 48 North America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 49 North America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 50 North America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 51 North America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 52 North America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 53 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Country (2023–2034) (\$MN)

Table 54 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)

Table 55 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)

Table 56 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)

Table 57 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam

(2023–2034) (\$MN)

Table 58 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E

(2023–2034) (\$MN)

Table 59 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines

(2023–2034) (\$MN)

Table 60 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron

(2023–2034) (\$MN)

Table 61 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine

(2023–2034) (\$MN)

Table 62 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine

(2023–2034) (\$MN)

Table 63 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol

(2023–2034) (\$MN)

Table 64 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)

Table 65 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type

(2023–2034) (\$MN)

Table 66 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia

(2023–2034) (\$MN)

Table 67 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)

Table 68 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia

(2023–2034) (\$MN)

Table 69 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)

Table 70 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2023–2034) (\$MN)

Table 71 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 72 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 73 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 74 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 75 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 76 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 77 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 78 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 79 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Country (2023–2034) (\$MN)

Table 80 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)

Table 81 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)

Table 82 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)

Table 83 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2023–2034) (\$MN)

Table 84 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2023–2034) (\$MN)

Table 85 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2023–2034) (\$MN)

Table 86 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2023–2034) (\$MN)

Table 87 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2023–2034) (\$MN)

Table 88 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2023–2034) (\$MN)

Table 89 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2023–2034) (\$MN)

Table 90 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)

Table 91 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2023–2034) (\$MN)

Table 92 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2023–2034) (\$MN)

Table 93 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)

Table 94 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2023–2034) (\$MN)

Table 95 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)

Table 96 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics

(2023–2034) (\$MN)

Table 97 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 98 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 99 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 100 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 101 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 102 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 103 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 104 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 105 South America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2023–2034) (\$MN)

Table 106 South America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)

Table 107 South America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)

Table 108 South America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)

Table 109 South America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2023–2034) (\$MN)

Table 110 South America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2023–2034) (\$MN)

Table 111 South America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2023–2034) (\$MN)

Table 112 South America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2023–2034) (\$MN)

Table 113 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2023–2034) (\$MN)

Table 114 South America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2023–2034) (\$MN)

Table 115 South America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2023–2034) (\$MN)

Table 116 South America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)

Table 117 South America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2023–2034) (\$MN)

Table 118 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2023–2034) (\$MN)

Table 119 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)

Table 120 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2023–2034) (\$MN)

Table 121 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)

Table 122 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2023–2034) (\$MN)

Table 123 South America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 124 South America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 125 South America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 126 South America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 127 South America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 128 South America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 129 South America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 130 South America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

Table 131 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Country (2023–2034) (\$MN)

Table 132 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2023–2034) (\$MN)

Table 133 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2023–2034) (\$MN)

Table 134 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2023–2034) (\$MN)

Table 135 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By

Clonazepam (2023–2034) (\$MN)

Table 136 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2023–2034) (\$MN)

Table 137 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2023–2034) (\$MN)

Table 138 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2023–2034) (\$MN)

Table 139 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2023–2034) (\$MN)

Table 140 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2023–2034) (\$MN)

Table 141 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2023–2034) (\$MN)

Table 142 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2023–2034) (\$MN)

Table 143 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2023–2034) (\$MN)

Table 144 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2023–2034) (\$MN)

Table 145 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2023–2034) (\$MN)

Table 146 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2023–2034) (\$MN)

Table 147 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2023–2034) (\$MN)

Table 148 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2023–2034) (\$MN)

Table 149 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2023–2034) (\$MN)

Table 150 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2023–2034) (\$MN)

Table 151 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2023–2034) (\$MN)

Table 152 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 153 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) (\$MN)

Table 154 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2023–2034) (\$MN)

Table 155 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2023–2034) (\$MN)

Table 156 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2023–2034) (\$MN)

I would like to order

Product name: Tardive Dyskinesia Therapeutics Market Forecasts to 2034 – Global Analysis By Product Type (Valbenazine, Deutetrabenazine, Clonazepam, Vitamin E, Benzodiazepines, Ondansetron, Tetrabenazine, Reserpine, Propranolol and Dopamine-Depleting Agents), Disease Type, Route Of Administration, Distribution Channel and By Geography

Product link: <https://marketpublishers.com/r/T2FB72B881BEEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2FB72B881BEEN.html>